Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses，Cancer Cell. 2014 Jan 13;25(1):37-48.
发布时间：2014年02月11日
Cancer Cell. 2014 Jan 13;25(1):37-48. doi: 10.1016/j.ccr.2013.12.004.
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang X1, Zhang X2, Fu ML3, Weichselbaum RR4, Gajewski TF3, Guo Y5, Fu YX6.
Abstract
Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.
附件下载：
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses，Cancer Cell. 2014 Jan 13;25(1):37-48.
Cancer Cell. 2014 Jan 13;25(1):37-48. doi: 10.1016/j.ccr.2013.12.004.
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang X1, Zhang X2, Fu ML3, Weichselbaum RR4, Gajewski TF3, Guo Y5, Fu YX6.
Abstract
Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.
相关报道：http://www.ibp.cas.cn/kyjz/zxdt/201402/t20140211_4031859.html
文章链接：http://www.ncbi.nlm.nih.gov/pubmed/24434209